查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830813

2025年肺癌篩檢全球市場報告

Lung Cancer Screening Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，肺癌篩檢市場呈現強勁成長勢頭，市場規模從2024年的30.3億美元增加至2025年的33.3億美元，複合年成長率達9.9%。這段歷史性時期的成長可歸因於菸草使用率的上升、人們對早期癌症檢測認知的提高、政府舉措和篩檢計畫的不斷擴展、老年人口的成長以及私人診斷中心的普及率的提高。

預計未來幾年肺癌篩檢市場將強勁成長，到2029年將達到47.9億美元，複合年成長率為9.5%。預測期內的成長動力來自諸多因素，例如日益加重的空氣污染和職業暴露負擔、支持早期篩檢益處的新興臨床證據、保險覆蓋範圍的擴大、都市化進程加快和生活方式的改變，以及放射科基礎設施投資的增加。這段時期的主要趨勢包括：雲端基礎影像處理平台的整合、放射組學和影像分析的重大進展、可攜式和照護現場影像處理設備的開發、決策支援系統與放射科工作流程的整合，以及基於非侵入性生物標記篩檢的進展。

肺癌篩檢是一種預防策略，旨在及早發現肺癌，通常在出現明顯症狀之前即可發現。它針對的是因某些健康和生活方式因素而處於高風險的人。該過程的目標是及早發現肺組織的異常變化或生長，從而增加有效治療的機會，並降低疾病的整體影響。

肺癌篩檢的主要診斷方法是低劑量螺旋CT和胸部X光檢查。低劑量螺旋CT可以減少輻射，並產生詳細的肺部截面影像，從而能夠高靈敏度地早期發現肺部異常。這些檢查適用於各種類型的肺癌，例如非小細胞肺癌和小細胞肺癌，以及不同年齡段，例如50歲以上和50歲以下。它們的終端用戶眾多，包括醫院、診所和診斷中心。

2025年春季美國突然提高關稅以及由此引發的貿易摩擦嚴重影響了醫療保健產業，尤其是關鍵醫療設備、診斷設備和藥品的供應。醫院和醫療機構面臨進口手術器械、影像設備以及注射器和導管等消耗品成本上漲的問題。這些成本上漲給醫療保健預算帶來了巨大壓力，導致一些醫療機構推遲設備升級或將成本轉嫁給患者。此外，原料和零件的關稅阻礙了基本藥品和醫療設備的生產，造成了供應鏈瓶頸。為此，該行業正在籌資策略多樣化，盡可能促進本地生產，並倡導緊急醫療產品免關稅。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供肺癌篩檢市場統計數據，例如全球市場規模、區域佔有率、肺癌篩檢市場佔有率的競爭對手、詳細的肺癌篩檢細分市場、市場趨勢以及肺癌篩檢行業的商機。本肺癌篩檢市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

吸菸率上升預計將推動肺癌篩檢市場的成長。由於壓力水平上升，吸煙（主要是吸入煙草燃燒產物產生的煙霧）的人數正在增加，越來越多的人將吸煙作為一種應對機制。肺癌篩檢有助於應對這一趨勢，因為它支持及早發現與吸菸相關的健康風險，促進戒菸，並支持減少菸草使用的公共衛生舉措。例如，根據國家統計局 2023 年 9 月的數據，2022 年英國約有 450 萬成年人（佔總人口的 8.7%）報告每天或偶爾使用電子煙，高於 2021 年的 7.7%。因此，吸菸率的上升正在推動肺癌篩檢市場的發展。

肺癌篩檢市場的主要企業正專注於人工智慧 (AI) 創新，以提高乳房攝影篩檢影像的早期發現和診斷準確性。諸如正常標記之類的技術可提高診斷準確性，減少假陽性，並自動識別無異常觀察的掃描結果，從而幫助確定病例的優先順序以進行進一步審查。 2025 年 5 月，韓國醫療科技公司 Lunit Inc. 推出了 INSIGHT CXR4，這是一款由人工智慧驅動的下一代胸部 X 光分析解決方案。此系統可協助放射科醫師檢測 12 種胸部異常，包括肺結節、肺炎和急性骨折，並結合目前和歷史影像比較等功能，用於早期疾病檢測和臨床決策支援。

2022年8月，美國醫學影像軟體供應商Intelerad 醫療圖像 Systems Inc.收購了PenRad Technologies, Inc.，收購金額未揭露。透過此次收購，Intelerad旨在擴展其乳房X光攝影和肺癌篩檢服務，提高放射科醫生的工作流程效率，並改善患者預後。 PenRad Technologies Inc.專注於肺癌篩檢軟體，此次收購將增強Intelerad先進的影像解決方案能力。

肺癌篩檢市場包括提供放射學解讀、診斷追蹤程序、患者風險評估和遠距醫療諮詢等服務的營業單位所獲得的收益。市場價值還包括服務供應商銷售或包含在服務產品中的相關商品的價值。僅包括營業單位之間交易或銷售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球肺癌篩檢：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球肺癌篩檢市場：成長率分析
  • 全球肺癌篩檢市場表現：規模與成長，2019-2024
  • 全球肺癌篩檢市場預測：2024-2029年及2034年規模與成長
  • 全球肺癌篩檢：總目標市場（TAM）

第6章 市場細分

  • 全球肺癌篩檢市場按診斷類型、表現和預測，2019-2024 年、2024-2029 年、2034 年
  • 低劑量螺旋電腦斷層掃描
  • 胸部X光檢查
  • 全球肺癌篩檢市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌
  • 全球肺癌篩檢市場：依年齡層分類，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 50歲或以上
  • 50歲以下
  • 全球肺癌篩檢市場：按最終用戶、實際結果和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院和診所
  • 診斷中心
  • 其他最終用戶
  • 全球肺癌篩檢市場：低劑量螺旋電腦斷層掃描細分（按類型）、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 篩檢
  • 診斷
  • 後續行動
  • 全球肺癌篩檢市場：胸部X光相片細分（按類型）、績效及預測，2019-2024年、2024-2029年、2034年
  • 後部 前部
  • 水平的
  • 可攜式的

第7章 區域和國家分析

  • 全球肺癌篩檢市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球肺癌篩檢市場：依國家、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 肺癌篩檢市場：競爭格局
  • 肺癌篩檢市場：公司簡介
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Canon Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Medtronic Plc
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • GE Healthcare Technologies Inc.
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.
  • Shimadzu Corporation
  • NeoGenomics Laboratories Inc.
  • Freenome Holdings Inc.
  • Biodesix Inc.
  • Lunit Inc.
  • Infervision
  • Riverain Technologies
  • VisionGate
  • Delfi Diagnostics Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年肺癌篩檢市場：提供新機會的國家
  • 2029年肺癌篩檢市場：細分領域帶來新機會
  • 2029年肺癌篩檢市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r37802

Lung cancer screening is a preventive strategy aimed at detecting cancer in the lungs at an early stage, often before any noticeable symptoms appear. It targets individuals at higher risk due to specific health or lifestyle factors. The goal of this process is to identify abnormal changes or growths in lung tissue early, improving the chances of effective treatment and reducing the overall impact of the disease.

The primary diagnostic methods for lung cancer screening include low-dose spiral computed tomography (CT) scans and chest X-rays. Low-dose spiral CT scans use reduced radiation to produce detailed cross-sectional images of the lungs, allowing early detection of lung abnormalities with high sensitivity. These scans are applied for different lung cancer types, including non-small cell lung cancer and small cell lung cancer, and across various age groups, such as individuals aged 50 and older or below 50. They are utilized by multiple end users, including hospitals, clinics, diagnostic centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The lung cancer screening market research report is one of a series of new reports from The Business Research Company that provides lung cancer screening market statistics, including the lung cancer screening industry global market size, regional shares, competitors with the lung cancer screening market share, detailed lung cancer screening market segments, market trends, and opportunities, and any further data you may need to thrive in the lung cancer screening industry. This lung cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to the rising prevalence of tobacco use, increasing awareness of early cancer detection, expansion of government initiatives and screening programs, a growing geriatric population, and greater penetration of private diagnostic centers.

The lung cancer screening market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the increasing burden of air pollution and occupational exposures, rising clinical evidence supporting the benefits of early screening, expanding availability of insurance coverage, growing urbanization and lifestyle changes, and rising investments in radiology infrastructure. Key trends in this period include the integration of cloud-based imaging platforms, advancements in radiomics and image analytics, development of portable and point-of-care imaging devices, incorporation of decision support systems into radiology workflows, and progress in non-invasive biomarker-based screening.

The rising smoking rates are expected to drive growth in the lung cancer screening market. Smoking, the inhalation of smoke from burning substances, primarily tobacco has been increasing due to rising stress levels, with more individuals turning to smoking as a coping mechanism. Lung cancer screening helps address this trend by enabling early detection of smoking-related health risks, encouraging smoking cessation, and supporting public health initiatives to reduce tobacco use. For example, according to the Office for National Statistics in September 2023, around 4.5 million adults in Great Britain, or 8.7% of the population, reported using e-cigarettes either daily or occasionally in 2022, up from 7.7% in 2021. Therefore, the growing prevalence of smoking is fueling the lung cancer screening market.

Key players in the lung cancer screening market are focusing on innovations in artificial intelligence (AI) to improve early detection and diagnostic precision in chest imaging. Technologies such as normal flagging enhance diagnostic accuracy, reduce false positives, and help prioritize cases that require further review by automatically identifying scans with no abnormal findings. In May 2025, Lunit Inc., a South Korea-based medtech company, launched INSIGHT CXR4, its next-generation AI-powered chest X-ray analysis solution, now CE MDR-certified for use across Europe. This system assists radiologists by detecting 12 chest abnormalities including lung nodules, pneumonia, and acute bone fractures and incorporates features such as current-prior image comparison to support early disease detection and clinical decision-making.

In August 2022, Intelerad Medical Systems Inc., a U.S.-based medical imaging software provider, acquired PenRad Technologies, Inc. for an undisclosed sum. Through this acquisition, Intelerad aims to expand its offerings in mammography and lung cancer screening, improving workflow efficiency for radiologists and enhancing patient outcomes. PenRad Technologies Inc. specializes in lung cancer screening software, strengthening Intelerad's capabilities in advanced imaging solutions.

Major players in the lung cancer screening market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Abbott Laboratories Inc., Canon Inc., Medtronic Plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, and Delfi Diagnostics Inc.

North America was the largest region in the lung cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer screening market includes revenues earned by entities by providing services such as radiology interpretation, diagnostic follow-up procedures, patient risk assessment, and telehealth consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lung cancer screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Diagnosis Type: Low Dose Spiral Computed Tomography Scan; Chest-X-Ray
  • 2) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
  • 3) By Age Group: 50 And Older; Below 50
  • 4) By End-User: Hospitals And Clinics; Diagnostic Centers; Other End-Users
  • Subsegments:
  • 1) By Low Dose Spiral Computed Tomography Scan: Screening; Diagnostic; Follow-Up
  • 2) By Chest X-Ray: Posterior Anterior; Lateral; Portable
  • Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; AstraZeneca Plc; Abbott Laboratories Inc.; Canon Inc.; Medtronic Plc; Siemens Healthineers AG; Koninklijke Philips N.V.; GE Healthcare Technologies Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Shimadzu Corporation; NeoGenomics Laboratories Inc.; Freenome Holdings Inc.; Biodesix Inc.; Lunit Inc.; Infervision; Riverain Technologies; VisionGate; Delfi Diagnostics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Screening Market Characteristics

3. Lung Cancer Screening Market Trends And Strategies

4. Lung Cancer Screening Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Lung Cancer Screening Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Lung Cancer Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Lung Cancer Screening Market Growth Rate Analysis
  • 5.4. Global Lung Cancer Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Lung Cancer Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Lung Cancer Screening Total Addressable Market (TAM)

6. Lung Cancer Screening Market Segmentation

  • 6.1. Global Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Low Dose Spiral Computed Tomography Scan
  • Chest-X-Ray
  • 6.2. Global Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer
  • 6.3. Global Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 50 And Older
  • Below 50
  • 6.4. Global Lung Cancer Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Centers
  • Other End-Users
  • 6.5. Global Lung Cancer Screening Market, Sub-Segmentation Of Low Dose Spiral Computed Tomography Scan, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Screening
  • Diagnostic
  • Follow-Up
  • 6.6. Global Lung Cancer Screening Market, Sub-Segmentation Of Chest X-Ray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Posterior Anterior
  • Lateral
  • Portable

7. Lung Cancer Screening Market Regional And Country Analysis

  • 7.1. Global Lung Cancer Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Lung Cancer Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Screening Market

  • 8.1. Asia-Pacific Lung Cancer Screening Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Screening Market

  • 9.1. China Lung Cancer Screening Market Overview
  • 9.2. China Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Screening Market

  • 10.1. India Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Screening Market

  • 11.1. Japan Lung Cancer Screening Market Overview
  • 11.2. Japan Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Screening Market

  • 12.1. Australia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Screening Market

  • 13.1. Indonesia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Screening Market

  • 14.1. South Korea Lung Cancer Screening Market Overview
  • 14.2. South Korea Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Screening Market

  • 15.1. Western Europe Lung Cancer Screening Market Overview
  • 15.2. Western Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Screening Market

  • 16.1. UK Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Screening Market

  • 17.1. Germany Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Screening Market

  • 18.1. France Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Screening Market

  • 19.1. Italy Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Screening Market

  • 20.1. Spain Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Screening Market

  • 21.1. Eastern Europe Lung Cancer Screening Market Overview
  • 21.2. Eastern Europe Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Screening Market

  • 22.1. Russia Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Screening Market

  • 23.1. North America Lung Cancer Screening Market Overview
  • 23.2. North America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Screening Market

  • 24.1. USA Lung Cancer Screening Market Overview
  • 24.2. USA Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Screening Market

  • 25.1. Canada Lung Cancer Screening Market Overview
  • 25.2. Canada Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Screening Market

  • 26.1. South America Lung Cancer Screening Market Overview
  • 26.2. South America Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Screening Market

  • 27.1. Brazil Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Screening Market

  • 28.1. Middle East Lung Cancer Screening Market Overview
  • 28.2. Middle East Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Screening Market

  • 29.1. Africa Lung Cancer Screening Market Overview
  • 29.2. Africa Lung Cancer Screening Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Lung Cancer Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Lung Cancer Screening Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Screening Market Competitive Landscape And Company Profiles

  • 30.1. Lung Cancer Screening Market Competitive Landscape
  • 30.2. Lung Cancer Screening Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Canon Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Screening Market Other Major And Innovative Companies

  • 31.1. Medtronic Plc
  • 31.2. Siemens Healthineers AG
  • 31.3. Koninklijke Philips N.V.
  • 31.4. GE Healthcare Technologies Inc.
  • 31.5. Quest Diagnostics Incorporated
  • 31.6. Agilent Technologies Inc.
  • 31.7. Shimadzu Corporation
  • 31.8. NeoGenomics Laboratories Inc.
  • 31.9. Freenome Holdings Inc.
  • 31.10. Biodesix Inc.
  • 31.11. Lunit Inc.
  • 31.12. Infervision
  • 31.13. Riverain Technologies
  • 31.14. VisionGate
  • 31.15. Delfi Diagnostics Inc.

32. Global Lung Cancer Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Screening Market

34. Recent Developments In The Lung Cancer Screening Market

35. Lung Cancer Screening Market High Potential Countries, Segments and Strategies

  • 35.1 Lung Cancer Screening Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Lung Cancer Screening Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Lung Cancer Screening Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer